Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. (ACRV), a clinical-stage biotechnology company, reported a net loss of $77.9 million for FY 2025, an improvement from $80.6 million in FY 2024, driven by reduced operating expenses of $84.1 million compared to $89.2 million prior year. Research and development expenses decreased to $60.0 million from $64.0 million, primarily due to fewer milestones in the ACR-368 program ($23.0 million vs. $34.1 million), offset by increased spending on ACR-2316 ($7.5 million vs. $3.4 million). General and administrative expenses fell to $24.1 million from $25.2 million. No revenue was generated, consistent with pre-commercial status. Other income, net, was $6.2 million, down from $8.6 million due to lower interest income. Balance sheet shows total assets of $129.7 million, with cash, cash equivalents, and investments at $118.6 million, providing runway into Q2 2027. Cash used in operations was $63.7 million, partially offset by $66.1 million from investing activities. Forward-looking, the company advances ACR-368 Phase 2b trials in endometrial cancer with 39% ORR in biomarker-positive patients and ACR-2316 Phase 1, expecting continued losses but pipeline progress.

Key Takeaways